Document:

<PAGE>

                                  CONFIDENTIAL
                           EXCLUSIVE LICENSE AGREEMENT

          This Exclusive License Agreement (this "AGREEMENT") is entered into as
of the 23rd day of December, 1997 (the "Effective Date") by and between the Fred
Hutchinson Cancer Research Center, a Washington non-profit corporation (the
"FHCRC"), and Rosetta Inpharmatics, Inc., a Delaware corporation (the
"LICENSEE").

                                    RECITALS

          A. FHCRC is the owner by assignment from Stephen H. Friend and Leland
Hartwell (the "Inventors") of the PATENT RIGHTS as defined in this Agreement
together with certain confidential information relating thereto;

          B. FHCRC is committed to a policy that ideas or creative works
produced at FHCRC should be used for the greatest possible public benefit and
believes that every reasonable incentive should be provided for the prompt
introduction of such ideas into public use, all in a manner consistent with the
public interest;

          C. LICENSEE desires to obtain an exclusive worldwide license in order
to practice the above referenced invention covered by the PATENT RIGHTS in the
United States and in certain foreign countries, and to manufacture, use and sell
in the commercial market the products made in accordance therewith; and

          D. FHCRC is willing to grant such a license to LICENSEE subject to the
terms and conditions of this Agreement.

                              TERMS AND CONDITIONS

          The parties agree as follows:

                             ARTICLE 1- DEFINITIONS

         1.1 PATENT RIGHTS means rights of FHCRC in, to and under the issued
United States patents and patent applications listed in APPENDIX A, the
inventions described therein, as well as all continuations and divisions
thereof, all continuations-in-part to the extent one or more of their claims are
directed to the subject matter of the patent applications listed in APPENDIX A
as of the Effective Date hereof, reissues, reexaminations, extensions and
foreign counterparts thereof, which will automatically be deemed incorporated in
and added to this Agreement and shall periodically be added to APPENDIX A.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

         1.2 LICENSED PROCESSES means any process described and claimed in
PATENT RIGHTS.

         1.3 LICENSED PRODUCT means a product described and claimed in the
PATENT RIGHTS or a product that is manufactured or covered by one or more
LICENSED PROCESSES.

         1.4 AFFILIATE means any company, corporation, or business in which
LICENSEE owns or controls at least a fifty percent (50%) ownership interest (or
such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction) or which directly or indirectly owns
or controls more than a fifty percent (50%) ownership interest in LICENSEE.

         1.5 TECHNICAL INFORMATION means inventions (whether or not patentable),
processes, materials, formulas and know-how directly related to the subject
matter of the PATENT RIGHTS that are developed by the Inventors and owned or
controlled by FHCRC as of the date of this Agreement or hereafter. All TECHNICAL
INFORMATION shall be communicated to LICENSEE in writing.

         1.6 TECHNOLOGY means any and all (a) PATENT RIGHTS and (b) TECHNICAL
INFORMATION supplied by FHCRC to LICENSEE.

         1.7 IMPROVEMENT means any invention, discovery or know-how (whether
or not patentable) which (a) is an improvement or modification of the
TECHNOLOGY or otherwise directly relates to the subject matter of the PATENT
RIGHTS; (b) is not licensed as of the Effective Date; (c) is made within [***]
from the Effective Date hereof; (d) is conceived or reduced to practice by
one or more of the Inventors; and (e) is owned by FHCRC or LICENSEE with the
right to license it.

                                ARTICLE 2- GRANT

         2.1 EXCLUSIVE LICENSE. FHCRC hereby grants to LICENSEE and LICENSEE
accepts, subject to the terms and conditions hereof, the exclusive worldwide
license, under the PATENT RIGHTS, to make, have made, use, sell, import, offer
for sale and have sold the LICENSED PRODUCTS, to practice the TECHNOLOGY and to
practice the LICENSED PROCESSES, for all uses in all fields, for the Term
permitted in Section 3.1 of this Agreement (the "License"). The License includes
the right to grant sublicenses, subject to the provisions of Section 2.2(f)
below.

         2.2 RESTRICTIONS ON LICENSE. Notwithstanding any other provision of
this Agreement, the License is subject to the following policies, obligations
and/or conditions:

                  (a) FHCRC's Patents and Inventions Policy adopted September
30, 1983,

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -2-

<PAGE>

Public Laws 96-517 and 98-620 and FHCRC's obligations under agreement
with other sponsors of research. Any right granted in this Agreement greater
than that permitted under Public Laws 96-517 or 9 8-620 shall be subject to
modification as may be required to conform to the provisions of the statutes.

                  (b) LICENSEE agrees during the period of exclusivity of the
License that any LICENSED PRODUCT produced for sale in the United States will be
manufactured substantially in the United States.

                  (c) For research purposes only and not for any commercial
purpose, FHCRC has the right to make and to use, but not to sublicense the
TECHNOLOGY without LICENSEE'S written consent (which consent will not be
unreasonably withheld if the sublicense is to an academic or research
institution, is for research purposes only and such institution agrees to be
bound by the restrictions of this Section 2.2(c)). FHCRC agrees that it will not
use the TECHNOLOGY in research subject to licensing or consulting obligations to
a third party (except for the federal government), without the written consent
of LICENSEE.

                  (d) LICENSEE shall use reasonable effort to introduce the
LICENSED PRODUCTS into the commercial market as soon as practicable, consistent
with sound and reasonable business practices and judgment, and thereafter
endeavor to keep LICENSED PRODUCTS reasonably available to the public.

                  (e) FHCRC shall have the right to render this Agreement
non-exclusive at any time after [***] of the Effective Date upon sixty (60)
days prior written notice to LICENSEE if, in FHCRC's reasonable judgment,
LICENSEE has not put a LICENSED PRODUCT into commercial use directly or
through a sublicense and is not keeping the LICENSED PRODUCT reasonably
available to the public, or is not demonstrably engaged in research,
development, manufacturing, marketing or licensing, as appropriate, directed
toward these ends. In making this determination FHCRC shall take into account
the normal course of such programs conducted with sound and reasonable
business practices and judgment, then-prevailing market conditions, the
existence of new or more competitive technologies, and shall take into
account the reports provided hereunder by LICENSEE. FHCRC's determination to
render this Agreement non-exclusive will become effective at the end of the
sixty (60) day notice period unless LICENSEE shall have demonstrated
fulfillment of its obligation under this Section 2.2(e).

                  (f) LICENSEE may grant sublicenses for any rights granted
under the License. All sublicenses granted by LICENSEE hereunder shall include a
requirement that the sublicensee use reasonable efforts to bring the subject
matter of the sublicense into commercial use consistent with Section 2.2(e) and
shall expressly bind the sublicensee to meet LICENSEE's obligations to FHCRC
under this Agreement relating to sublicenses, including, but not limited to,
obligations under Section 2.2(e). Copies of all executed sublicense agreements
pertaining to any rights granted under the License shall promptly be provided to
FHCRC. FHCRC agrees to maintain each such sublicense agreement and all
information relating thereto in confidence.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -3-

<PAGE>

          2.3 IMPROVEMENTS. FHCRC and LICENSEE agree to promptly disclose to
each other all IMPROVEMENTS to the TECHNOLOGY in a writing, in sufficient
detail for LICENSEE and FHCRC to evaluate each such IMPROVEMENT. FHCRC grants
to LICENSEE the option to an exclusive license in each such IMPROVEMENT owned
by FHCRC for a period of [***] from the date of disclosure to LICENSEE.
LICENSEE shall have the right to exercise the option to an exclusive license
to such IMPROVEMENT at any time during the [***] option period by notifying
FHCRC in writing. Upon exercise of the option in writing, the IMPROVEMENT
will be included in the TECHNOLOGY and licensed in the License without
additional charge to LICENSEE. If the option is not exercised by LICENSEE,
FHCRC shall be free to license such IMPROVEMENT to a third party or parties
without any obligation to LICENSEE. LICENSEE hereby grants to FHCRC a
nonexclusive, irrevocable, royalty-free license for research purposes to its
interests in any IMPROVEMENT; provided that such IMPROVEMENT will be deemed
to be TECHNOLOGY under this Agreement and subject to the restrictions set
forth in Section 2.2(c). Notwithstanding the foregoing, to the extent FHCRC
develops any improvement to the TECHNOLOGY based on Proprietary Information
owned by LICENSEE that would be an IMPROVEMENT but for the fact that it was
conceived or reduced to practice by someone other than one or more of the
Inventors, FHRCR shall first offer such improvement to LICENSEE. For a period
of ninety (90) calendar days following notice to LICENSEE by FHCRC of such
improvement, FHCRC and LICENSEE shall in good faith endeavor to negotiate an
agreement with respect to LICENSEE's rights to such improvement. In the event
FHCRC and LICENSEE fail to enter into such agreement within such ninety (90)
day period, FHCRC shall, for a period of one year thereafter, have the right
to enter into an agreement regarding such improvement with a third party
provided that the terms and conditions offered to such third party shall not
be more favorable than the terms and conditions last specified by FHCRC to
LICENSEE in a written proposal unless first offered to LICENSEE. Thereafter,
FHCRC shall be free to enter into an agreement regarding such improvement
with a third party without further restriction under this Section 2.3.

                          ARTICLE 3- TERM OF AGREEMENT

          The term of this Agreement commences on the Effective Date and,
subject to earlier termination as provided in Article 2.2(e), ends on the later
of(a) the expiration date of the last to expire of the PATENT RIGHTS and (b)
twenty (20) years from the Effective Date (the "Term") unless otherwise provided
in this Agreement.

                         ARTICLE 4- EQUITY AND PAYMENTS

          4.1 EQUITY. As partial consideration for the License, LICENSEE agrees
to issue to FHCRC shares of LICENSEE's Common Stock equal to four percent (4%)
of fully-diluted capital stock of LICENSEE immediately following the closing of
LICENSEE's Series A Preferred Stock financing. The Common Stock issued to FHCRC
shall be subject to the terms and conditions set forth in the Stock Purchase
Agreement attached hereto as APPENDIX B.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -4-

<PAGE>

          4.2 PAYMENTS. On June 30 of each year, commencing on June 30
following the date on which the first patent covered under the Patent Rights
is issued in the United States (the "United States Patent Issue Date") and
continuing thereafter until the earlier of (a) termination of this Agreement
or (b) the date on which the Company grants a sublicense to the Technology to
a non-Affiliate in a transaction where the aggregate value of the license
fees, research funding and similar compensation to LICENSEE is greater than
[***], LICENSEE shall make an annual payment of [***] (the "ANNUAL PAYMENT").

                              ARTICLE 5 - REPORTING

          5.1 RESEARCH AND DEVELOPMENT PLAN. Within sixty (60) days following
execution of this Agreement, LICENSEE shall provide to FHCRC a written research
and development plan and business plan for introducing LICENSED PRODUCTS into
commercial use.

          5.2 ANNUAL REPORTS. LICENSEE shall provide written reports within
sixty (60) days after December 31 of each calendar year which shall include the
following information: reports of progress on research and development,
regulatory approvals, manufacturing, sublicensing, marketing and sales during
the preceding twelve (12) months as well as plans for the coming year. If
LICENSEE's progress differs from that anticipated in the plan provided to FHCRC
under Section 5.1, LICENSEE shall explain the reasons for the difference and
propose modified plans for FHCRC's review and comments, which comments shall be
given serious consideration by LICENSEE. LICENSEE shall also provide any
reasonable additional data FHCRC requires to evaluate LICENSEE's performance.

          5.3 FINANCIAL REPORTS. LICENSEE shall provide to FHCRC quarterly
fmancial statements for the immediately preceding quarter within thirty (30)
days after the end of each quarter.

          5.4. CONFIDENTIALITY OF REPORTS. All such reports shall be maintained
in confidence by FHCRC, except as required by law, including Public Laws 96-517
and 98-620.

                    ARTICLE 6- DOMESTIC AND FOREIGN PATENT FILING
                                             AND MAINTENANCE

          6.1 RESPONSIBILITY. Throughout the term of this Agreement, LICENSEE,
at its own expense, shall have the right, but shall not be obligated, to
prepare, file, prosecute and defend against third party oppositions any and all
United States and foreign patent applications, and to maintain any and all
United States and foreign patents included within the PATENT RIGHTS; PROVIDED,
HOWEVER, that LICENSEE shall first consult with FHCRC as to the preparation,
filing, prosecution and defense of such applications and maintenance of such
patents and shall promptly furnish to FHCRC copies of all documents relevant to
such preparation, filing, prosecution, defense, or maintenance and shall keep
FHCRC fully advised of the same. FHCRC shall have the right to review and make
recommendations with respect to all such patent applications and patents and
proceedings relating thereto. In the event of a dispute between LICENSEE and

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -5-

<PAGE>

FHCRC as to such preparation, filing, prosecution, defense, or maintenance,
FHCRC's decision shall be controlling on such subject. In the event that
LICENSEE elects not to file, prosecute, or defend such applications or maintain
such patents, LICENSEE shall so notify FHCRC in writing not less than sixty (60)
days prior to such action, in which event FHCRC shall have the right to conduct
such filing, prosecution, defense, or maintenance. Notwithstanding any of the
foregoing, FHCRC shall have the right, on any reasonable basis, and upon written
notice to LICENSEE, to take over and assume responsibility for the preparation,
filing, prosecution and defense of any and all United States and foreign patent
applications included within PATENT RIGHTS and maintenance of any and all United
States and foreign patents included within PATENT RIGHTS. In the event that
FHCRC conducts such filing, prosecution, defense, or maintenance as provided
herein, FHCRC shall first consult with LICENSEE as to such preparation, filing,
prosecution, defense, or maintenance and shall keep LICENSEE fully advised of
the same; in such case, LICENSEE shall have the right to review and make
recommendations with respect to all such patent applications and patents and
proceedings relating thereto.

          6.2 REIMBURSEMENT. LICENSEE shall reimburse FHCRC for all reasonable
and documented expenses FHCRC has incurred for the preparation, filing,
prosecution and maintenance of PATENT RIGHTS, including any interference
proceedings, and shall reimburse FHCRC for all such expenses incurred in
connection with the PATENT RIGHTS.

          6.3 NOTICE. Each party shall provide to the other prompt notice as to
all matters which come to its attention and which may affect the preparation,
filing, prosecution, defense or maintenance of any such patent applications or
patents. FHCRC and LICENSEE shall cooperate fully and in good faith in the
preparation, filing, prosecution, defense and maintenance of PATENT RIGHTS and
of all patents and patent applications licensed to LICENSEE hereunder, including
the execution of all papers and instruments so as to enable FHCRC to apply for,
to prosecute and to maintain patent applications and patents in FHCRC's name in
any country.

          6.4 NON-PAYMENT. If LICENSEE elects not to pay the expenses of a
patent application or patent included within PATENT RIGHTS, LICENSEE shall
notify FHCRC not less than sixty (60) days prior to such action and shall
thereby surrender its rights under Section 2.1 of this Agreement with respect to
such patent or patent application.

                             ARTICLE 7- ENFORCEMENT

          7.1 NOTICE OF INFRINGEMENT. Each party agrees to notify the other
promptly of any infringement of the PATENT RIGHTS of which such party becomes
aware.

          7.2 ACTION BY LICENSEE. During the Term, subject to FHCRC prior
written consent (not to be unreasonably withheld), LICENSEE has the right to
prosecute any infringements of the PATENT RIGHTS, at its sole expense, and FHCRC
hereby agrees that LICENSEE may include FHCRC as a party plaintiff in any such
suit, without expense of FHCRC. The total cost

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -6-

<PAGE>

of any such action commenced or defended solely by LICENSEE shall be borne by
LICENSEE and LICENSEE shall keep any recovery or damages for infringement
derived from the action. Before LICENSEE commences any such infringement action,
LICENSEE shall give careful consideration to the views of FHCRC and to potential
effects on the public interest in making its decision whether or not to commence
such an action. FHCRC agrees to cooperate reasonably in any such action
initiated by LICENSEE including supplying essential documentary evidence and
making essential witnesses then in FHCRC's employment available at LICENSEE's
expense.

          7.3 ACTION BY FHCRC. If LICENSEE fails to initiate an infringement
action within ninety (90) days after notification or knowledge of the basis for
such action and LICENSEE is not already a party in an infringement action
including any patent included within PATENT RIGHTS, or if FHCRC reasonably
withholds its consent pursuant to Section 7.2, FHCRC shall have the right, and
in the case of reasonably withholding its consent pursuant to Section 7.2 shall
be obligated, to prosecute at its own expense all infringements of the PATENT
RIGHTS, and LICENSEE hereby agrees that FHCRC may include LICENSEE as a party
plaintiff in any such suit, without expense to LICENSEE. The total cost of any
such action commenced or defended solely by FHCRC shall be borne by FHCRC and
FHCRC shall keep any recovery or damages for past infringement derived from the
action.

                    ARTICLE 8- INDEMNIFICATION AND INSURANCE

         8.1 INDEMNIFICATION. LICENSEE assumes responsibility for and shall
defend, indemnify and hold FHCRC, its directors, officers, managers, agents,
students, doctors and employees (the "Indemnified Parties") harmless from any
and all liability, losses, expenses, damages, assessments and claims arising out
of or resulting from (a) the use, sale or any disposition of LICENSED PRODUCTS
by LICENSEE or its AFFILIATES, (b) the practice of the LICENSED PROCESSES by
LICENSEE or its AFFILIATES, or (c) the use, sale or other disposition of the
LICENSED PRODUCT or LICENSED PROCESSES by others who receive LICENSED PRODUCTS
or LICENSED PROCESSES directly or indirectly from LICENSEE, its AFFILIATES,
agents or representatives. Notwithstanding the foregoing, LICENSEE shall have no
obligation to indemnify and hold harmless the Indemnified Parties (i) if the
claim is found to be based upon the gross negligence or willful misconduct of
any of the Indemnified Parties, or (ii) if the Indemnified Parties fail to give
LICENSEE prompt notice of any claim it receives and such failure materially
prejudices LICENSEE, or (iii) solely to the extent of indemnification for legal
fees and disbursements of counsel of the Indemnified Parties, unless LICENSEE is
given the opportunity to control the defense of such action, or (iv) unless
LICENSEE is given the opportunity to approve any settlement; and provided
further that, except in the event of a material conflict of interest, LICENSEE
will not be liable for attorney's fees of the Indemnified Parties after assuming
control of the defense or settlement.

         8.2 INSURANCE. Upon the earlier of any: (a) testing or use in human
subjects or (b) sale of a LICENSED PRODUCT, LICENSEE will have FHCRC named as an
additional insured on LICENSEE's product liability insurance policies, with
limits consistent with sound business practice. Such policies shall not be
terminated without thirty (30) days prior written notice to

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -7-

<PAGE>

FHCRC. LICENSEE shall provide FHCRC with written evidence of the insurance
and a copy of the policy upon request.

         8.3 LEGAL ACTION. In the event any legal action is commenced against
LICENSEE involving the TECHNOLOGY, whether or not FHCRC is named as a ~5arty to
the legal action, LICENSEE shall keep FHCRC or its attorney nominee fully
advised of the progress of the legal action and shall reimburse FHCRC for its
reasonable legal costs (including attorney's fees) incurred as a result of
FHCRC's monitoring of such action, FHCRC's being named a party to any such legal
action, or when FHCRC's employees or agents are called as witnesses therein or
asked to testify for or consult with LICENSEE in connection therewith. FHCRC
agrees to cooperate with LICENSEE, to the extent reasonably possible, in any
legal action brought pursuant to this Section 8.3.

                             ARTICLE 9- ARBITRATION

          Any dispute, other than a question relating to patent validity or
infringement, between the parties hereunder which cannot be resolved by good
faith negotiation between the parties over a period of at least sixty (60) days
shall be resolved by arbitration before a panel of three arbitrators under the
then current rules and procedures of the American Arbitration Association (the
"AAA"), or other rules and procedures as the parties may agree. Each party shall
bear its own costs incurred in connection with such arbitration and the fees,
expenses and costs of the AAA, the arbitrator(s) and the arbitration proceeding
not incurred solely by one party shall be divided equally between the parties.
The arbitral award shall be binding and conclusive on both parties and may be
enforced in any court of competent jurisdiction.

                      ARTICLE 10- TERMINATION OF AGREEMENT

          10.1 TERMINATION ON PAYMENT DEFAULT. At FHCRC's option, FHCRC may
terminate this Agreement effective thirty (30) days after giving written notice
in the event LICENSEE fails to pay any Annual Payment or other amounts owed
under this Agreement when due, unless the payment default is cured or shown to
be non-existent within such thirty (30) day period, in which case the Agreement
will remain in effect.

          10.2 TERMINATION ON OTHER DEFAULTS. This Agreement may be
terminated by either party upon a material breach by the other party other
than a payment default which is governed by Section 10.1, effective [***]
after giving written notice to the breaching party of such termination under
this Section 10.2 and specifying such breach, unless the default is cured or
shown to be non-existent within the [***] period, in which case the Agreement
will remain in effect.

          10.3 TERMINATION ON BANKRUPTCY OR INSOLVENCY. Subject to any
provisions of the federal bankruptcy laws limiting rights of termination, this
Agreement will automatically terminate if LICENSEE files for protection under
federal bankruptcy laws, becomes insolvent,

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -8-

<PAGE>

makes an assignment for the benefit of creditors, appoints or suffers
appointment of a receiver or trustee over its property, files a petition under
any bankruptcy or insolvency act or has any such petition filed against it or
files for dissolution.

          10.4 TERMINATION BY LICENSEE. LICENSEE shall have the right to
terminate this Agreement at any time upon [***] prior written notice to FHCRC.

          10.5 EFFECT OF TERMINATION ON SUBLICENSES. Any sublicenses granted by
LICENSEE under this Agreement shall provide for termination or assignment to
FHCRC, at the option of FHCRC, of LICENSEE's interest therein upon termination
of this Agreement.

          10.6 SALE OF PRODUCTS ON TERMINATION. In the event that FHCRC
terminates this Agreement as permitted herein, LICENSEE shall have the right
for [***] to sell all LICENSED PRODUCTS on hand at the time of receipt of
notice of termination if any and all payments due FHCRC are paid when due in
accordance with this Agreement.

          10.7 EFFECT OF TERMINATION. Upon termination of the Agreement for any
reason, and subject to LICENSEE's rights under Section 10.6, each party shall
return to the other party all TECHNOLOGY owned by such other party and
thereafter continue to maintain the confidentiality thereof, and refrain from
use thereof or the disclosure thereof to any third party as required by Article
13, and all other rights in TECHNOLOGY and LICENSED PRODUCTS granted under
Article 2 shall expire and revert to the owner thereof. Upon termination of this
Agreement, each party will turn over to the other party all Proprietary
Information owned by such other party and all documents or data storage media
containing any such Proprietary Information owned by such other party and any
and all copies thereof, and each party will delete all Proprietary Information
owned by such other party from its documents or data storage media. Should
either party terminate this Agreement as permitted herein, the other party shall
not be able to claim from the terminating party, any damages or compensation for
losses or expenses incurred solely as a result of the termination. FHCRC shall
be entitled to retain all equity issued and payments made under this Agreement,
notwithstanding termination of this Agreement for any reason.

          10.8 SURVIVAL OF RIGHTS AND DUTIES. Rights and duties hereunder which
by their terms or nature survive the termination or expiration of this Agreement
shall so survive such termination or expiration, including without limitation
duties under Sections 5.3, 7, 8, 9, 10.6, 10.7, 12, 13, 16.1, 16.7, 16.8, 16.9
and 16.10.

                    ARTICLE 11- REPRESENTATIONS AND COVENANTS

          11.1 FHCRC REPRESENTATIONS AND WARRANTIES. FHCRC represents and
warrants that all right, title, and interest in the patent applications or
patents comprising the PATENT RIGHTS listed in APPENDIX A have been or will be
assigned to it and are owned by it (subject to Government Rights under 35 U.S.C.
Section 200 et seq.), that FHCRC has the authority to issue licenses under the
PATENT RIGHTS, that all corporate action of FHCRC required to authorize

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -9-

<PAGE>

and perform this Agreement and the transactions contemplated hereby has been
taken; that this Agreement has been duly executed and delivered by FHCRC and is
a legal, valid and binding obligation of FHCRC and that FHCRC is duly organized
and validly existing under the laws of the State of Washington.

          11.2 FHCRC DISCLAIMERS. FHCRC disclaims all implied or express
warranties of any nature whatsoever concerning the validity or scope of the
PATENT RIGHTS licensed hereunder. FHCRC does not warrant that such PATENT RIGHTS
may be exploited by LICENSEE, an AFFILIATE, or sublicensee without infringing
other patents. FHCRC EXPRESSLY DISCLAIMS ANY AND ALL EXPRESS WARRANTIES, EXCEPT
THOSE STATED IN THIS ARTICLE 11, AND FURTHER DISCLAIMS ANY AND ALL IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS OF THE TECHNOLOGY, LICENSED PROCESSES
OR LICENSED PRODUCTS FOR ANY PARTICULAR USE OR PURPOSE.

          11.3 LICENSEE REPRESENTATIONS AND WARRANTIES. LICENSEE represents and
warrants to FHCRC that all corporate action of LICENSEE required to authorize
and perform this Agreement and the transactions contemplated hereby has been
taken; that this Agreement has been duly executed and delivered by LICENSEE and
is a legal, valid and binding obligation of LICENSEE; that the execution,
delivery and performance of this Agreement will not, with OR without the giving
of notice or the lapse of time or both violate any judgment, order, writ, or
decree of any court applicable to LICENSEE or result in the breach of or
conflict with or constitute a default under any corporate charter, bylaw,
commitment, contract or other agreement or instrument to which LICENSEE is a
party; that LICENSEE is duly organized and validly existing under the laws of
the State of Delaware and that it has obtained and will at all times during the
Term hold and comply with all licenses, permits and authorizations necessary to
LICENSEE's complete and timely performance of its obligations under this
Agreement which are required under any applicable statutes, laws, ordinances,
rules and regulations of the United States as well as those of all applicable
foreign governmental bodies, agencies and subdivisions, having, asserting or
claiming jurisdiction over LICENSEE or LICENSEE's performance of the terms of
this Agreement. In particular, LICENSEE:

                  (a) will be responsible for obtaining all necessary United
States Food and Drug Administration approvals and all approvals required by
similar governmental bodies or agencies of all applicable foreign countries; and

                  (b) understands and acknowledges that the transfer of certain
commodities and technical data is subject to United States laws and regulations
controlling the export of such commodities and technical data, including all
Export Administration Regulations of the United States Department of Commerce.
These laws and regulations, among other things, prohibit or require a license
for the export of certain types of technical data to certain specified
countries. LICENSEE hereby agrees and gives written assurance that it will
comply with all United States laws and regulations controlling the export of
commodities and technical data, that it will be solely responsible for any
violation of such by LICENSEE or its AFFILIATES or sublicensees,

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -10-

<PAGE>

and that it will defend and hold FHCRC harmless in the event of any legal action
of any nature occasioned by such violation.

                               ARTICLE 12- NOTICES

          All communications, including payments, notices, demands or requests
required OR permitted to be given hereunder, shall be given in writing and shall
be: (a) personally delivered; (b) sent by facsimile or other electronic means of
transmitting written documents; or (c) sent to the parties at their respective
addresses indicated herein by registered or certified U.S. mail, return receipt
requested and postage prepaid, or by private overnight mail courier service. The
respective addresses to be used for all such payments, notices, demands or
requests are as follows:

       If to FHCRC:      Fred Hutchinson Cancer Research Center
                         1100 Fairview Avenue North, C2M-027
                         Seattle, Washington 98109
                         Attention:  Catherine J. Hennings, Director,
                         Technology Transfer
                         Facsimile:   (206) 667-4732

       With copies to:   Douglas J. Shaeffer, Esq.
                         Fred Hutchinson Cancer Research Center
                         1100 Fairview Avenue North, LM-254
                         Seattle, Washington 98109
                         Facsimile: (206) 667-6590

       If to LICENSEE:   Rosetta Inpharmatics, Inc.
                         12040 - 115th Avenue N.E., Suite 210
                         Kirkland, WA 98034
                         Attention: President
                         Facsimile: (425) 821-5354

       With copies to:   Venture Law Group
                         4750 Carillon Point
                         Kirkland, WA 98033
                         Attention:   William W. Ericson
                         File No. 15822.012
                         Facsimile:  (425) 739-8750

If personally delivered, such communication shall be deemed delivered upon
actual receipt. If electronically transmitted pursuant to this Article 12, such
communication shall be deemed delivered when transmitted. If sent by overnight
courier pursuant to this Article 12, such communication shall be deemed
delivered within twenty-four (24) hours of deposit with such courier. If sent by
U.S. mail pursuant to this Article 12, such communications shall be deemed
delivered as of the date of delivery indicated on the receipt issued by the
relevant postal service,

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -11-

<PAGE>

or, if the addressee fails or refuses to accept delivery, as of the date of such
failure or refusal. Any party to this Agreement may change their address for the
purposes of this Agreement by giving notice in accordance with this Article.

                 ARTICLE 13- CONFIDENTIALITY AND NON-DISCLOSURE

         13.1 PROPRIETARY INFORMATION. Any and all information in any form
relating to the TECHNOLOGY furnished to either party (or its agents or
employees) by the other party (or its laboratories or agents or employees),
including but not limited to information regarding or relating to devices,
biological materials, methods, processes, data, drawings, documentation, patent
applications, know how and product development plans, is confidential,
proprietary, information and any and all such information is hereinafter
referred to as "Proprietary Information."

         13.2 EXCEPTIONS TO PROPRIETARY INFORMATION. As used herein,
"Proprietary Information" does not include information:.

                  (a) that at the time of disclosure to the receiving party is
  or later becomes generally available to the public through no fault of the
  receiving party;

                  (b) that is demonstrated to have been in the receiving party's
  possession prior to the time of disclosure by the disclosing party;

                  (c) that is demonstrated by a preponderance of the evidence to
  have been independently developed by the receiving party's personnel without
  reference to Proprietary Information of the disclosing party; and

                  (d) received from a third party, unless such information is
  obtained subject to a confidential disclosure agreement.

          13.3 USE OF PROPRIETARY INFORMATION. Each party agrees: (a) to hold in
strict confidence and trust and maintain as confidential all Proprietary
Information disclosed by the other party; (b) not to disclose any such
Proprietary Information or any information derived therefrom to any person,
except to those employees or legal counsel of the receiving party who are
required to receive the Proprietary Information for the purposes described in
this Agreement and who are bound by the provisions of this Agreement; and (c) to
use the Proprietary Information only for the purposes described in this
Agreement.

          13.4 OWNERSHIP OF PROPRIETARY INFORMATION. Each party agrees that all
Proprietary Information disclosed by the other party will at all times be and
remain the sole property of the disclosing party and the disclosing party is the
sole owner of all patents, copyrights and other intellectual property rights and
other proprietary rights related to the Proprietary Information disclosed by it
and conceived or made by the disclosing party's employees.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -12-

<PAGE>>

          13.5 TERM OF CONFIDENTIALITY. The obligations of confidentiality
provided herein shall continue in force and effect for [***] from the date of
termination of this Agreement, whether by lapse of the Term hereof or
otherwise, unless extended or limited by mutual agreement executed in writing
by an officer of each party; PROVIDED, HOWEVER, that if this Agreement is
terminated before the end of the Term due to a default by LICENSEE, the
obligation of confidentiality shall continue for [***] from the end of the
Term assuming no early termination.

                           ARTICLE 14- PATENT MARKING

          Subsequent to the issuance of any patent included in the PATENT RIGHTS
and provided FHCRC advises LICENSEE of the patent number or numbers of any such
issued patents, LICENSEE agrees to mark and to have marked by its sublicensees
every LICENSED PRODUCT manufactured, used or sold in the United States by
LICENSEE, its AFFILIATES or its sublicensees in accordance with the statutes of
the United States relating to the marking of patented articles. All LICENSED
PRODUCTS shipped to or sold in other countries shall be marked in such a manner
as to conform with the patent laws and practice of the countries of manufacture
or sale.

                          ARTICLE 15- RIGHT TO PUBLISH

          Nothing in this Agreement shall be construed as prohibiting either
party from presenting or publishing any of the results of their own research
on the TECHNOLOGY, including without limitation research results which
constitute Proprietary Information; PROVIDED, HOWEVER, that each party agrees
to provide the other party with a copy of any such presentation or
publication at least [***] prior to submission or presentation and further
agrees to delay publication for a period not to exceed [***], which is
sufficient to allow the other party to take steps necessary to protect any
intellectual property, including the filing of any patent applications and/or
deletion of its confidential information.

                            ARTICLE 16- MISCELLANEOUS

          16.1 APPLICABLE LAW. The rights and obligations of the parties under
this Agreement shall be governed by and construed in accordance with the laws of
the State of Washington.

          16.2    NO MODIFICATION. This Agreement may not be amended except by
an instrument in writing signed by both parties.

          16.3 ASSIGNMENT. The Agreement shall be binding on the parties hereto
and upon their respective heirs, administrators, successors and assigns. This
Agreement may not be assigned by LICENSEE or by operation of law without the
prior written consent of FHCRC, which consent shall not be unreasonably
withheld; provided, that LICENSEE may assign this Agreement without FHCRC's
consent to any entity that acquires all or substantially all of its assets or
business relating to LICENSED PRODUCTS and LICENSED PROCESSES, by merger or

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -13-

<PAGE>

otherwise.

          16.4 NON-PROFIT STATUS. LICENSEE acknowledges that FFICRC is a
non-profit organization qualifying for and holding the status of an exempt
organization under Section 50l(c)(3) of the United States Internal Revenue Code
("SECTION 501(c)(3) STATUS"). If the Internal Revenue Service (the "IRS")
determines, or a determination by FHCRC based on advice of legal or tax counsel
is reasonably made, that any part or all of this Agreement will jeopardize
FHCRC's Section 501(c)(3) Status, the parties agree to meet and confer in good
faith to amend this Agreement to the extent necessary to satisfy IRS
requirements for retention of FHCRC's Section 501(c)(3) Status. If FHCRC and
LICENSEE cannot agree within thirty (30) days after commencing negotiations
regarding the amendments to be made to this Agreement in order for FHCRC to
retain its Section 501(c)(3) Status, FHCRC may terminate this Agreement
effective upon giving written notice to LICENSEE of termination under this
Section 16.4.

          16.5 CONFLICTS WITH GRANTS. LICENSEE understands and acknowledges that
agreements between FHCRC and agencies of the United States government funding
FHCRC's programs may contain clauses granting patent and/or other rights to the
agencies or the U.S. government. LICENSEE agrees that the rights granted to it
under this Agreement shall be subject to any rights of the agencies and the U.S.
government. If a conflict arises, the provisions of any U.S. government agency
funding agreement and/or regulation shall prevail over any conflicting
provisions of this Agreement and FHCRC will have no liability to LICENSEE as a
result of such conflict.

          16.6 BOARD OBSERVER. During the Term, FHCRC shall be entitled to have
one representative of FHCRC attend meetings of the Board of Directors of
LICENSEE, which representation shall be Leland Hartwell or such other
representative as FHCRC and LICENSEE shall mutually agree upon. LICENSEE agrees
to give FHCRC timely notice of Board of Directors meetings of LICENSEE.
Notwithstanding the foregoing, LICENSEE may exclude the FHCRC representative
from certain meetings or portions of certain meetings if LICENSEE reasonably
determines that attendance of the FHCRC representative would jeopardize
attorney-client privilege or proprietary rights of LICENSEE, violate
confidentiality requirements of a third party or otherwise be illegal or
improper.

          16.7 USE OF NAME. No party shall use the name of the other party or
reveal the terms of this Agreement in any publicity or advertising without the
prior written approval of the other party, except that (a) any party may use the
text of a written statement approved in advance by the other party without
further approval; (b) any party shall have the right to identify the other party
and to disclose the terms of this Agreement as required by applicable securities
laws or other applicable law or regulation; and (c) any party may disclose that
a licensing relationship exists between the parties and may disclose the name of
the other party in that context.

          16.8 NOTICES. All letters, documents, or other materials of a written
or physical nature, required by or relating to this Agreement shall be in
English and sent to the party at the address given in Article 12.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -14-

<PAGE>

          16.9 INDEPENDENT PARTIES. The parties to this Agreement are
independent contractors and not agent of the other. This Agreement shall not
constitute a partnership or joint venture, and neither party may be bound by the
other to any contract, arrangement or understanding except as specifically
stated herein.

         16.10 SEVERABILITY. Should a court of competent jurisdiction later
  consider any provision of this Agreement to be invalid, illegal, or
  unenforceable, it shall be considered severed from this Agreement. All other
  provisions, rights and obligations shall continue without regard to the
  severed provision, provided that the remaining provisioni of this Agreement
  are in accord with the intention of the parties.

         16.11 PROCEEDINGS. In the event any party to this Agreement commences
  any action or proceeding, including an appeal of an action or proceeding,
  against the other, or otherwise retains an attorney, by reason of any breach
  or claimed breach of any provision of this Agreement, or to seek a judicial
  declaration of rights hereunder or judicial or equitable relief, the
  prevailing party in such action or proceeding shall be entitled to recover its
  reasonable attorneys' fees and costs. Venue of any such legal or equitable
  action shall lie in Seattle, Washington. Each of LICENSEE and FHCRC hereby
  submits to the jurisdiction of the Federal District Court of Western
  Washington located in Seattle, Washington, and hereby agrees to accept service
  of process by certified mail, return receipt requested, effective upon
  delivery to LICENSEE or FHCRC, as the case may be.

         16.12 COUNTERPARTS. This Agreement may be executed simultaneously in
  any number of counterparts, each of which shall be deemed an original, but all
  of which together shall constitute one and the same instrument.

                            [Signature page follows:

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                      -15-

<PAGE>

FRED HUTCHINSON CANCER RESEARCH CENTER         ROSETTA INPHARMATICS, INC.

By: /s/                                        By: /s/ John J. King, II
   -----------------------------------             ---------------------------

Printed                                        Printed
Name:                                          Name: John J. King, II
     ---------------------------------               -------------------------

Title:                                         Title: Sr. Vice President & Co.
      --------------------------------                ------------------------

Date:                                          Date: 1/12/97
     ---------------------------------               -------------------------

                 SIGNATURE PAGE TO EXCLUSIVE LICENSE AGREEMENT

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

                                   Appendix A
                                   ----------

                         PATENT APPLICATIONS AND PATENTS

<TABLE>
<CAPTION>

                        Patent                                              File or
Patent NO.          Applicant No.                          Country        Issue Date    Title/Inventor
----------          -------------                          -------        ----------    --------------
<S>                 <C>                                    <C>            <C>           <C>

                    [***]                                   [***]            [***]      [***]

                    [***]                                   [***]            [***]      [***]

</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.<PAGE>

                         INTERNAL USE LICENSE AGREEMENT

Effective as of Nov. 30, 1998 (the "EFFECTIVE DATE"). Affyrnetrix. Inc., a
Delaware corporation ("Affymetrix") and Rosetta Inpharmatics, Inc., a Delaware
corporation ("Licensee") (each a "Party" and together "the Parties"), agree as
follows:

1. DEFINITIONS.

1.1 "ABE," which stands for Array Based Experiment, means a single experiment
involving hybridization of a labeled sample on a Nucleic Acid Array licensed
hereunder and that is covered at the time and place of the experiment by one or
more valid claims of a patent claim within the Licensed Patents. A "valid claim"
shall include a claim that has not been held to be invalid by a final judgement
from which no appeal can be taken. If labeled samples (including the same
sample) are consecutively hybridized to a single Nucleic Acid Array, then the
number of ABEs is equal to the number of consecutive hybridizations. If two
differently labeled samples arc mixed and simultaneously hybridized to a single
Nucleic Acid Array, then there has been one ABE.

1.2 "Affiliate" means any corporation or other business entity controlled by.
controlling, or wider common control with a Party, but only for so long as such
Affiliate remains an Affiliate of a Party, and only if such Affiliate is bound
in writing by the terms of this Agreement. For this purpose, "control" means
direct or indirect beneficial ownership of more than 50% of; (i) the voting
stock or other controlling equity interest in, or (ii) the revenue, of such
corporation or other business. References to Licensee in this Agreement will
include Licensee's Affiliates.

1.3 "Array Maker" means a device used to fabricate Nucleic Add Arrays by
mechanical fabrication methods. For clarity, the parties understand that
"mechanical fabrication" does not include controlled direction of
electromagnetic energy at a portion of a support (e.g. fabrication through
photolithographic synthesis methods), but does include the use of an inkjet
system to place nucleic acids on a support.

1.4 "Licensed Patent(s)" means the U.S. and Foreign Patents (and reissues,
renewals, and extensions thereof) and Patent applications set forth on Exhibit
A. as well as any U.S. or foreign application (including divisionals,
continuations, and continuations-in-part) claiming priority to any of the
foregoing and patents issuing thereon, as well as reissues, renewals, and
extensions thereof.

1.5 "Nucleic Acid Array" means (i) an array fabricated solely by placing only
fully synthesized nucleic acids (clonal polynucleotides or other presynthesized
polynucleotides, with no further fabrication of nucleic acids) at defined
locations on a solid support or (ii) an array fabricated solely by synthesizing
oligonucleotides using an inkjet head to deposit nucleotides at defined
locations on a solid support without using controlled direction of
electromagnetic energy. In the case of both (i) and (ii), all of such nucleic
acids may not represent more than 8,000 genes/expressed sequence tags; provided,
however, during the periods of this Agreement in which Licensee has purchased an
unlimited number of ABEs there shall be no limit on the number of
genes/expressed sequence tags that Licensee may represent on a single Nucleic
Acid Array.

2. LICENSE. During the term of this Agreement, Affymetrix grants Licensee a
nontransferable, nonsublicensable, nonexclusive, worldwide, royalty-bearing
license under the Licensed Patents, to internally use Array Makers and make
(but not have made, sell, import, distribute or lease) and internally use
Nucleic Acid Arrays made from such Array Makers for analyzing the presence,
absence, or level of expressed messenger RNA in cells for academic and
commercial research use only. For clarity, the Parties understand that
diagnostic applications are not being licensed.

2.1 This Agreement does not grant Licensee a license to:

(a) transfer a Nucleic Acid Array to any third party or

(b) provide services to any third party with respect to a Nucleic Acid Array.
For clarity, the Parties understand that biological research activities
involving Nucleic Add Arrays conducted by Licensee within a collaboration that
meets the requirements of Section 2.1(c)(ii) are permitted; or

(c) distribute, license or otherwise make available to a third party any data
or database that is obtained from the use of a Nucleic Acid Array, except as
follows:

        i) Licensee may license data obtained from a Nucleic Acid Array to a
        third party licensee specifically related to a particular compound,
        drug, target, pathway or transcript state of a cell that has been
        discovered or analyzed through use of the Nucleic Acid Array, provided
        that such third party licensee (or its direct distributors or
        sublicensees) pays substantial consideration for the right to develop
        and market such compound, drug or target with the bone fide intent to do
        so in accordance with such third party licensee's commercial policies in
        effect from time to time; or

         ii) Licensee may transfer data to a third party when such data is
         obtained within a bona fide collaboration with such third party (a
         "Collaborator") in which: (A) the Collaborator provides substantial
         scientific input to experimental design, (B) the collaborative
         relationship is set forth in an agreement signed by the Licensee and
         the Collaborator prior to the use of any Nucleic Acid Arrays to
         generate such data, and (C) Licensee retains material intellectual
         property rights in substantial discoveries or inventions that arise
         from such data, including know-how if there are no patent rights
         directly associated with such know-how and such know-how has
         significant value as compared to other intellectual property arising
         from the collaboration. Bona fide collaborations do not include
         arrangements whose primary purpose is to give third party access to
         data or databases or provide nucleic acid hybridization services, or

         iii) Licensee may transfer data to a third party so long as Licensee
         receives no consideration or other quid-pro-quo for such transfer and
         such data is not made preferentially available to customers of Licensee
         (e.g. such transfer cannot be contingent on the third party and
         Licensee exchanging other goods, services or intellectual property), or

(d) identify polymorphisms in genes/expressed sequence tags or perform
genotyping analysis.

2.2 Licensee may make the data described in Section 2. l(c)(i)-(iii) (`Permitted
Data") available to third parties only pursuant to written agreements containing
obligations that: (a) are no less restrictive than those in Section 2.1; and (b)
explicitly benefit Affymetrix by providing Affymetrix the right to enforce the
provisions of such agreement that correspond to Section 2.1 hereof in the event
that Licensee does not or cannot enforce such provisions itself and (c) prohibit
such third parties from sublicensing or otherwise further distributing such
Permitted Data except as set forth in Section 2.1 (c)(i). Licensee agrees not to
exceed the scope of the licenses grimed under this Agreement.

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                       1
<PAGE>

3 ROYALTIES. In consideration of Licensee's right to use at least one Licensed
Patent, Licensee will pay to Affymetrix: (a) an annual "Usage Royalty," and (b)
a one-time license issue fee of [***].

3.1 EasyAccess-TM- "Gold" and "Silver" customers are entitled to additional
discounts of [***] from the Usage Royalty, respectively. However, Licensee's
EasyAccess discount shall only apply during those years of this Agreement in
which Licensee has maintained such EasyAccess status fur at least seven
months in such year. In the event Affymetrix substantially redefines the Gold
and Silver EasyAccess marketing programs following the Effective Date,
Affymetrix agrees to offer Licensee discounts similar to those set forth in
this Section consistent with any then-prevailing marketing programs that
require financial commitments similar to the Gold and Silver EasyAccess
programs as of the Effective Date.

3.2 The annual Usage Royalty is set forth in the following table and is based on
the number of ABEs that Licensee is permitted to conduct within a single year
and Licensee's annual research and development budget (including its Affiliates)
as reported in audited financial statements.

                           LICENSEE ANNUAL R&D BUDGET

<TABLE>
<CAPTION>
                                  Between
# of annual ABEs   up [***]        [***]       [***]
----------------------------------------------------------
<S>               <C>            <C>          <C>
[***]              [***]          [***]        [***]
[***]              [***]          [***]        [***]
[***]              [***]          [***]        [***]
[***]              [***]          [***]        [***]
</TABLE>

3.3 Unused ABEs cannot be canned over from year-to-year. Nucleic Acid Arrays
that are provided to Licensee by a third party that has been licensed by
Affymetrix to provide such Nucleic Acid Arrays to Licensee shall not be included
in the royalty calculation.

4. PAYMENT. Upon execution of this Agreement. Licensee shall pay the license
issue fee. Licensee agrees to pay an annual Usage Royalty at [***] which
corresponds to [***] ABEs ("Maximum Annual ABEs") for use during each year of
this Agreement.

4.1 If during any year of this Agreement Licensee's ABE usage exceeds its
Maximum Annual ABEs: (a) Licensee shall promptly notify Affymetrix, (b)
Licensee's Maximum Annual ABEs and Usage Royalty shall increase to at least the
next higher volume amount (or higher, if Licensee elects) set forth in the above
table, and (c) the anniversary date of this Agreement shall be deemed to be the
date Affymetrix receives such notice. If Licensee notifies Affymetrix in writing
at least [***] prior to the anniversary date of this Agreement that Licensee
desires to increase or decrease their Maximum Annual ABEs, then Licensee's Usage
Royalty obligation shall be adjusted as set forth in the above table for the
next year.

4.2 During each year of this Agreement. Licensee agrees to pay the annual Usage
Royalty in [***] installments commencing at thc end of the first
calendar quarter that follows the Effective Date. If Licensee's ABE usage
exceeds its Maximum Annual ABE,, all remaining [***] payments due for such
year shall be immediately due and Licensee's first [***] installments for
Licensee's increased Usage Royalty shall be due at the end of the next [***].

4.3 If within one year following the Effective Date Affymetrix has felled to
enter into at least [***] Qualifying Deal [***], then Affymetrix and Licensee
shall meet to discuss readjusting the annual Usage Royalty fee structure, but
in no event shall the annual Usage Royalty fee structure be decreased by more
than [***]. A "Qualifying Deal" shall mean an agreement between Affymetrix
and a licensee with the following criteria (i) the licensee has a R & D
budget of less than [***], and (ii) the license agreement contains an annual
Usage Royalty fee structure and covenants not to sue that are substantially
similar to the ones set forth in this Agreement or which are more favorable
to Affymetrix than the ones set forth in this Agreement. Any readjustment to
the annual Usage Royalty fee structure shall only persist until Affymetrix
has entered into [***] Qualifying Deal [***], and thereafter, the annual Usage
Royalty fee structure set forth in this Agreement shall be [***].

4.4 In the event Licensee selects a Usage Royalty corresponding to an unlimited
number of annual ABE,, Licensee shall pay Affymetrix an additional annual
royalty of [***] per Datapoint for all ABEs in access of [***] ABEs per year
that arc used in connection with providing data to third parties, where
"Datapoint' shall mean a measurement of the presence, absence, or level of
contiguous sequence of expressed messenger RNA in a single biological sample as
measured by a Nucleic Acid Array.

5.1 AUDIT. On each anniversary of this Agreement, an officer of Licensee will
deliver to Affymetrix a statement certifying (i) that Licensee's ABE usage
did not exceed the Maximum Annual ABE in the preceding year, and (ii) the
number of ABEs used in the preceding year in connection with providing data
to third parties but only if such number exceeds [***], Licensee agrees to
maintain reasonable records to document the number of ABEs that Licensee
uses. Affymetrix may have a nationally recognized accounting firm under
obligations of confidentiality reasonably acceptable to Licensee examine
Licensee's relevant records. At any time during regular business hours end
upon [***]notice, but no more than [***] annually. If such examination
reveals a discrepancy between the royalties payable hereunder and the

royalties actually paid, Licensee will pay all such additional royalties,
together with the maximum interest permitted by law from the date when such
additional royalties would have been due, to Affymetrix [***] days of
receipt of notice from Affymetrix of such discrepancy. Any such examination
will be at Affymetrix' expense; provided that, if a deficiency of more than
[***] is discovered, the examination will be at Licensees expense and
Affymetrix shall not be deemed to have used its annual right to audit
Licensee.

5.2 COVENANTS. licensee covenants not to sue Affymetrix. or its Affiliates or
customers of either regarding any patented technology related to (1) the
sale, distribution, design, development or manufacturing of nucleic acid
probe arrays made using controlled direction of electromagnetic energy at a
support ("Affymetrix NAPAs") and any array readers/scanners, software,
assays, or packaging which may be used with Affymetrix NAPAs or (ii) the use
of Affymetrix NAPAs provided by Affymetrix or its Affiliates to their
customers and any array readers/scanners, software, assays, or packaging
which may be used by such customers with Affymetrix NAPAs; provided, however,
that such covenant not to sue does nor extend to: (A) the sale, distribution,
design, development or manufacturing of [***], or (B) the [***], or (C) the
[***], or (D) [***]

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                       2

<PAGE>

6. LIMITATIONS. Nothing in this Agreement will be construed as: (a) a warranty
or representation by Affymetrix as to the validity or scope of the Licensed
Patents; (b) a warranty or representation by Affymetrix that anything made,
used, or discovered under the rights granted in this Agreement does not or will
not infringe third party patents; (c) an obligation to bring actions against
third parties for infringement; (d) conferring the right to use any Affymetrix
trademark or designation; (e) conferring by implication, estoppel, or otherwise
any rights under any Affymetrix patents other than the Licensed Patents or any
rights not specifically granted herein; or (f) an obligation to furnish any
know-how not provided in the Licensed Patents. In no event will either Party be
liable for lost or prospective profits or indirect or consequential damages
resulting from this Agreement eve if the other Party has been advised of the
possibility of such damages.

7. INDEMNITY. Licensee will defend, indemnify, and hold Affymetrix harmless from
and against any liability, demands, damages, expenses and losses for death,
personal injury, illness, or property damage arising out of Licensee's use of
any method or apparatus under the Licensed Patents. As used in this Section 7,
"Affymetrix" includes its trustees, officers, agents, and employees. The
technology licensed hereby is experimental, and Licensee will take all
reasonable precautions to prevent death, personal injury, illness, and property
damages from use thereof.

8. TERMS AND TERMINATION. This Agreement will remain in effect for three years
following the Effective Date, and continue thereafter n renewing one year terms
until terminated by either party by providing notice to the other party at least
60 days prior to the anniversary date hereof. If either Party materially fails
to perform any obligations under this Agreement, the other Party may notify the
defaulting party of the default. If the defaulting Party has not materially
cured the default within 30 days after receiving such notice, the other Party
may terminate this Agreement upon 30 days' notice to the defaulting Party. Such
right to terminate will be in addition to, and without prejudice to the exercise
of, any other remedies available in law or equity. Sections 1, 2.2, 5.1, 6, 7,
9.1, 9.2 and 9.3 will survive termination or expiration of this Agreement.

9. GENERAL. Licensee covenants not to benchmark or otherwise compare performance
metrics such as sensitivity and specificity from Licensee's nucleic acid arrays
to any Affymetrix' nucleic acid arrays and disclose such comparison results to
third parties without the prior approval of Affymetrix which shall not be
unreasonable withheld. Licensee agrees not to disparage Affymetrix' personnel,
products or services. Licensee may not assign this Agreement by acquisition of
Licensee's assets or stock, by operation of law, or otherwise, without
Affymetrix's prior consent. In the event Licensee is acquired, Affymetrix will
not unreasonably withhold its consent to such an assignment. Affymetrix' consent
shall be deemed to have been reasonably withheld if Licensee proposes to merge
with an entity that is a party or an Affiliate of a party to litigation with
Affymetrix; provided, however, the foregoing proviso will not be effective in
the event Affymetrix initiates such litigation for the primary purpose of
preventing the assignment of this Agreement. No assignment of this Agreement
will be valid until the assignee has assumed all obligations under this
Agreement and the Usage Royalty has been adjusted to reflect the assignee's R&D
budget. If any provision of this Agreement is held invalid or unenforceable for
any reason, such unenforceability will not affect the enforceability of the
remaining provisions of this Agreement, and all provisions of this Agreement
will be construed so as to preserve the enforceability hereof. The waiver by
either Party of a breach of any provision of this Agreement by the other Party
will not be construed as a waiver of any succeeding breach of the same or any
other provision, nor will any delay on the part of either Party to exercise any
right that it may have hereunder operate as a waiver of any right by such Party.
In the event there is a dispute between the Parties in connection with this
Agreement, neither Party shall file a claim against the other Party in
connection with such dispute until thirty (30) days following notice to the
other Party and the Chief Executive Officer of each Party shall meet and discuss
potential solutions to such dispute during the thirty (30) days following notice
to the other Party and the Chief Executive Officer of each Party shall meet and
discuss potential solutions to such dispute during the thirty (30) day period.
Affymetrix represents and warrants that it owns or is the legal licensee of the
Licensed patents and that it has the right to enter into this Agreement for the
Licensed Patents.

9.1 NOTICE. All requests, consents, notices, and other communications under this
Agreement will be in writing and will be deemed to have been given upon the
confirmed facsimile transmission or prepaid express mailing to the address
below, or at such address as either Party may from time-to-time designate in
writing to the other Party.

To Affymetrix:    Affymetrix, Inc.
                  3380 Central Expressway
                  Santa Clara, CA 95051
                  Attention: General Counsel

To Licensee:      Rosetta Inpharmatics, Inc.
                  12040 115th Avenue N.E.
                  Kirkland, Washington 98034
                  Attention: Chief Operating Officer

9.2 ENTIRE AGREEMENT. This Agreement constitutes the entire agreement between
the parties relating to the subject matter thereof, and all prior negotiations,
representations, agreements, and understandings are merged into, extinguished
by, and completely expressed by it. This Agreement will be construed in
accordance with the laws of California without regard to its conflict of laws
rules.

9.3 CONFIDENTIALITY. The Parties will keep the terms of this Agreement in
confidence, except as may be required by regulatory agencies or courts or as
required by law, and will then use all reasonable precautions to keep the terms
of this Agreement confidential.

Signature: /s/ Stephen A. Fodor
           -----------------------------------------------
           Stephen P.A. Fodor, Ph.D.
           President and Chief Executive Officer
           Affymetrix, Inc.

Date: 30 Nov 98
      ----------------------------------------------------

Rosetta Inpharmatics, Inc.

Signature: /s/ John J. King II
          ------------------------------------------------

Name (Print): John J. King, II
              --------------------------------------------

Title: Senior VP & COO
       ---------------------------------------------------

Date: 30 November, 1998
      ----------------------------------------------------

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

                                       3
<PAGE>

                                                               EXHIBIT A

<TABLE>
<CAPTION>

                 COUNTRY      PATENT/                  TITLE OF INVENTION               AFFYMETRIX       FEATURE         STATUS
                            APPLICATION                                                  FILE NO.
                                NO.
  <S>            <C>        <C>            <C>                                         <C>          <C>                <C>

                                                        [  *    *    *]

</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

<TABLE>
<CAPTION>

                 COUNTRY      PATENT/                  TITLE OF INVENTION               AFFYMETRIX       FEATURE         STATUS
                            APPLICATION                                                  FILE NO.
                                NO.
  <S>            <C>        <C>            <C>                                         <C>          <C>                <C>

                                                        [  *    *    *]

</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

<TABLE>
<CAPTION>

                 COUNTRY      PATENT/                  TITLE OF INVENTION               AFFYMETRIX       FEATURE         STATUS
                            APPLICATION                                                  FILE NO.
                                NO.
  <S>            <C>        <C>            <C>                                         <C>          <C>                <C>

                                                        [  *    *    *]

</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

<PAGE>

<TABLE>
<CAPTION>

                 COUNTRY      PATENT/                  TITLE OF INVENTION               AFFYMETRIX       FEATURE         STATUS
                            APPLICATION                                                  FILE NO.
                                NO.
  <S>            <C>        <C>            <C>                                         <C>          <C>                <C>

                                                        [  *    *    *]

</TABLE>

*  Material has been omitted pursuant to a request for confidential treatment,
   and such material has been filed separately with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00007-of-00352.parquet"}]]